Newsfeeds - Spark Newswire

1 minute read

News

Alterity Therapeutics Announces Allowance of New Composition of Matter Patent by the United States Patent and Trademark Office

Today, 10:57 AM

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that a new composition of matter patent has been allowed by the United States Patent and Trademark Office (USPTO). The patent was allowed following expedited review by the USPTO.

ATHE

2 minute read

News

Alterity Therapeutics Announced Presentation of Data from the bioMUSE Natural History Study at the American Autonomic Society Annual Meeting

By Charles Gross

Today, 10:57 AM

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) today announced a poster presentation from the ongoing Biomarkers of Progression in Multiple System Atrophy (bioMUSE) natural history study was given at the American Autonomic Society (AAS) 2022 Annual Conference held November 2-5, 2022.

ATHE

2 minute read

Movers

12 Health Care Stocks Moving In Thursday’s After-Market Session

By Benzinga Insights

Today, 10:57 AM

Gainers Nuwellis (NASDAQ:NUWE) stock rose 13.9% to $0.28 during Thursday's after-market session. The company's market cap stands at $8.9 million.

ATHE

1 minute read

Here’s Why Alterity Therapeutics Shares Are Volatile

By Henry Khederian

Today, 10:57 AM

Alterity Therapeutics Ltd (NASDAQ: ATHE) shares are trading sharply lower by 14.29% to $0.48, reversing following earlier strength, after the company announced the approval of its Investigational New Drug application by the FDA to allow evaluation of ATH434 in individuals with Multiple System Atro

ATHE

3 minute read

Why O2Micro International Is Trading Higher By 7%; Here Are 25 Stocks Moving Premarket

By Lisa Levin

Today, 10:57 AM

Gainers

ADXN

2 minute read

Recap Of Thursday’s Biotech Catalysts – End Of the Day Summary

By Ragothaman Srinivasan

Today, 10:57 AM

Pfizer (NYSE:PFE) announced positive top-line data from the Phase 3 clinical trial RENOIR investigating its bivalent RSV prefusion F…

APTX

4 minute read

Stocks That Hit 52-Week Lows On Thursday

By Benzinga Insights

Today, 10:57 AM

During Thursday's trading, 50 companies set new 52-week lows.

ALLR

2 minute read

FDA
News

Alterity Therapeutics Doses First Patient in ATH434 Phase 2 Clinical Trial in Multiple System Atrophy

By Benzinga Newsdesk

Today, 10:57 AM

Alterity Therapeutics ((ASX: ATH, NASDAQ:ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today

ATHE

6 minute read

FDA
News

Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial For The Treatment Of Patients With Multiple System Atrophy

By Benzinga Newsdesk

Today, 10:57 AM

Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial for the Treatment of Patients with Multiple System Atrophy Multiple System Atrophy is a rare, rapidly progressive, neurodegenerative disease that causes

ATHE

44 minute read

Stocks That Hit 52-Week Lows On Wednesday

By Benzinga Insights

Today, 10:57 AM

On Wednesday, 807 companies reached new 52-week lows.

AADI